ArticleInfluenza and other respiratory viruses2026
Immune Priming and the Risk of COVID-19, Influenza, and Other Acute Respiratory Infections: Insights From an N3C Cohort.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune Priming and the Risk of COVID-19, Influenza, and Other Acute Respiratory Infections: Insights From an N3C Cohort.Influenza and other respiratory viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe emergence of SARS-CoV-2 and introduction of COVID-19 vaccines into immunologically naïve populations may alter the dynamics of other acute viral respiratory infections (viral ARIs) and vice versa. Competing forces, including viral interference, cross-reactive immunity, shared susceptibility, and immune dysregulation, may affect the risk. The potential net impact of various immune-priming events and their timing on the risk of viral ARIs is largely unknown.
methodsUsing data from the National Clinical Cohort Collaborative (N3C) COVID-19 Enclave, this retrospective population-based cohort study investigated the relationship between immune-priming events (COVID-19 and influenza vaccinations, and SARS-CoV-2, influenza, other, and unspecified viral ARIs) between January 2018 and September 2021 and the risk of viral ARIs during October 2021-April 2022. The sample included N = 608,725 individuals from seven data partners with well-ascertained COVID-19 and influenza vaccination data.
resultsEarly COVID-19 vaccination (December 2020-March 2021) and SARS-CoV-2 infection during the overlapping period (October 2020-March 2021) were associated with a lower risk of all outcomes, including non-SARS-CoV-2 infections. Off-season influenza vaccination (January-June 2021) was associated with a lower risk of SARS-CoV-2 and any viral ARI. Other priming events showed mixed associations, with a lack of evidence of stronger protection from more recent immune-priming events.
conclusionsThis exploratory analysis suggests potential crossprotection between viral ARIs that may inform vaccination strategies. While ascertainment and healthcare-seeking biases in electronic health records may inflate positive associations between infection outcomes and immune priming, negative (i.e., protective) associations are of potential public health significance and warrant further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.